关键词: 肺肿瘤诊断, 癌胚抗原, 糖类抗原125, 糖类抗原19-9, 神经特异性烯醇化酶, 铁蛋白

Abstract:

Objective To evaluate the application of combined five tumor markers, CEO, CA₁25, CA₁99, NSE and SF in diagnosing lung cancer in terms of enhancement in the early detection rate.Methods Using tumor markers protein chip, the serum CEA, CA₁25, CA₁9-9, NSE and SF levels in 73 cases of non-small cell lung cancer (NSCLC), 21 cases of benign pulmonary disease and 16 cases of normal controls were measured and compared.Results The levels of CEA, CA₁25, CA₁9-9, NSE and SF in patients with NSCLC were significantly higher than those in the group with benign lung diseases and in the control group( P <0.01). The sensitivity of CEA, CA₁25, CA₁9-9, NSE and SF were 79.5%, 56.2%, 56.2%, 52.1%, 57.5%, respectively, and the corresponding specificity 81.0%, 100%, 85.7%, 90.5%, 80.9%, respectively. Moreover, the sensitivity and specificity of the combined determinations including the five tumor markers were higher than those of the respective determination.Conclusion The serum CEA, CA₁25, CA₁9-9, NSE and SF levels are very valuable in diagnosis of lung cancer. The combined detection five tumor markers is recommended in clinical work.

Key words: lung cancer diagnosis, CEA, CA₁25, CA₁9-9, NSE, SF